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In the February 2011 issue of  SSMJ we covered the pathophysiology, and 
clinical and laboratory diagnosis of  malaria (1, 2, 3). In this article we 
deal with the treatment of  uncomplicated malaria. Management of  malaria 
among pregnant women and children, and treatment of  severe malana will 
be published in future issues of  this journal.
Uncomplicated malaria is “symptomatic malaria 
without signs of  severity or evidence (clinical or laboratory) 
of  vital organ dysfunction”. Cure is defined as “the 
elimination from the body of  the parasites that caused 
the illness. This prevents progression to severe disease, 
and additional morbidity associated with treatment failure 
(4)”.
The primary aim of  treatment is to cure the infection 
as rapidly as possible so it does not deteriorate into severe 
malaria. The public health (or secondary) aim is to reduce 
transmission to others and prevent the emergence and 
spread of  resistance to anti-malarial medicines.
Anti-malarial drugs
Anti-malarial drugs can be classified by their action on 
different stages of  the malaria parasite:
1. Tissue schizonticide (primaquine) 
2. Blood schizonticide (chloroquine, sulphadoxine-
pyrimethamine, quinine, mefloquine and artemisinins)
3. Gametocytocide (artemisinins and  
primaquine).
Anti-malarial combination treatments
Anti-malarial combination treatments are the 
simultaneous use of  two or more blood schizonticidal 
drugs with independent modes of  action and unrelated 
biochemical targets in the parasites (i.e. the partner drugs 
in a combination must be independently effective). They 
are recommended by World Health Organization (WHO) 
because they have the potential to:
delay the development of  resistance to the • 
individual anti-malarials in the combination
improve treatment outcomes• 
overcome the threat of  resistance of  plasmodium • 
falciparum to monotherapies.
Artemisinin derivatives should be one of  the drugs in 
a combination.
Artemisinin based combination therapies (ACTs)
ACT is a combination therapy where one of  the 
components is artemisinin or its derivative (artesunate, 
artemotil, artemether, dihydroartemisinin). Artemisinin 
derivatives are rapidly acting schizonticidal drugs capable of  
reducing parasite biomass by a factor of  104 each asexual 
life cycle. Another advantage of  artemisinin derivatives is 
their ability to kill gametocytes, hence interrupting malaria 
transmission.
To eliminate at least 90% of  the parasitaemia, a 3-day 
course of  the artemisinin is needed to cover up to three 
post-treatment asexual cycles of  the parasite. This leaves 
a much smaller number of  parasites (10%) for the partner 
drug to kill while its concentration in plasma remains 
high. 
ACTs recommended by WHO are:
Artesunate + amodiaquine • 
Artemether + lumefantrine • 
Artesunate + mefloquine • 
Artesunate + sulfadoxine-pyrimethamine • 
Dihydrortemisinin + piperaquine• 
For the treatment of  uncomplicated malaria in South 
Sudan:
The recommended first line medicine is • 
Artesunate/Amodiaquine.
The recommended second line medicine is • 
Artemether/Lumefantrine (Coartem®)
ACTs are available as:
Two medicines contained in one tablet i.e. they • 
are fixed-dose artemisinin based combination 
treatments.
Separate medicines packaged together (co-• 
packaged or co-blistered). However, the public 
ACT supply has shifted from co-blistered to 
co-formulated or Fixed Dose Combination of  
ASAQ.
 Vol 4. No 2. May 2011                                                                                                     Southern Sudan Medical Journal  31
MAIN ARTICLES
Treatment regimes
The WHO recommended treatment for treating 
uncomplicated P. falciparum malaria in non-pregnant 
adults is to give an artemisinin based combination therapy 
(ACT) for at least 3 days. The regimes for the anti-malarials 
recommended in South Sudan are (5, 6):
First line: Artesunate + amodiaquine
The total recommended treatment is 4 mg/kg body 
weight of  Artesunate (AS) and 10 mg base/kg body 
weight of  Amodiaquine (AQ) given once a day for 3 days.
(Table 1)
The tablets for each age group have different strengths, 
so they cannot be interchanged, combined or broken 
down as this can lead to overdosing or under dosing a 
patient. 
Patients must finish all 3 days of  treatment. Always give 
the first dose of  the treatment in the clinic and observe 
the patient swallowing the medicine.
Second line: Artemether+lumefantrine 
Patients must finish all 3 days of  treatment.  (Table 2)
Always give the first dose of  the treatment in the clinic 
and observe the patient swallowing the medicine. Explain 
that this ACT should be taken with food or fluids (fatty 
meals or milk) to improve its absorption, particularly 
on the second and third days of  treatment. If  vomiting 
occurs within half  an hour of  swallowing the medicine, 
the dose should be repeated 
and the patient should receive 
a replacement dose from the 
health worker.
The presence of  malaria 
parasites should be confirmed 
in all suspected cases. If  there 
is no means of  confirmation 
(RDT or microscopy) or if  
the tests are negative, but the clinician (after history and 
physical exam and other investigations) is still convinced 
that malaria is the cause of  illness, the patient should be 




Recurrence of  P. falciparum malaria can result from re-
infection or treatment failure - although it may be difficult 
to know the cause. Treat it as treatment failure if  fever and 
parasitaemia have not resolved or recur within two weeks 
of  treatment. Treatment failures may result from:
• drug resistance
• poor adherence or inadequate drug exposure (e.g. 
due to under-dosing, vomiting) or
• substandard medicines. 
Find out if  the patient vomited the previous treatment 
or did not complete a full course of  treatment. If  possible, 
confirm treatment failure by examining a blood slide.
 In many cases, failures are missed because patients 
who present with malaria are not asked whether they have 
received anti-malarial treatment within the preceding 1–2 
weeks. This should be a routine question in patients who 
present with malaria.
Age Infant 2 months – 
11 months
Toddler 1 – 5 yrs Child 6yrs – 13 yrs Adolescent/Adult 
≥14 yrs
Weight >4.5 – <9 kg >9 – <18 kg >18– <36 kg Over  36 kg
Tablet 25mgAS/67.5mgAQ 50mgAS/135mgAQ 100mgAS/270mgAQ 100mgAS/270mgAQ 
Day 1 1 tablet 1 tablet 1 tablet 2 tablet
Day 2 1 tablet 1 tablet 1 tablet 2 tablet
Day 3 1 tablet 1 tablet 1 tablet 2 tablet
Table 1. Artesunate Amodiaquine Fixed Dose Combination (Winthrop®)
Weight kg Age Day 1 Day 2 Day 3 Colour code of  package




























Table 2. Dosage of  Coartem® tablets (Artemether 20mg & Lumefantrine 120mg)
Southern Sudan Medical Journal                                                                                       Vol 4. No 2. May 2011    32
Management
Treatment failure within 14 days of  receiving an • 
ACT is unusual, but if  it occurs treat with a 2nd-
line antimalarial (i.e. Artemether /Lumefantrine).
Treatment failure after 14 days of  initial treatment • 
should be considered as a new infection and 
treated with the first-line ACT (i.e. Artesunate/
Amodiaquine).
Other aspects of management
Incorrect approaches to treatment
Do not:
• use artemisinins as monotherapy as this promotes 
resistance. 
Patients who cannot take oral medicine
Some patients need parenteral or rectal administration 
for 1–2 days until they can swallow and retain oral 
medication reliably. Although such patients may never 
show other signs of  severity, they should receive the same 
initial anti-malarial dose regimens as for severe malaria 
followed by a full 3-day course of  ACT.
Antipyretics
Fever is a key sign of  malaria and is associated with 
tiredness, weakness, headache, anorexia and often nausea. 
Treat with antipyretics and, if  necessary, fanning and 
tepid sponging. Antipyretics should be used if  core 
temperatures ≥ 38.5ºC. 
Paracetamol (acetaminophen) 15 mg/kg every 4 hours 
given orally or as a suppository is safe and usually well 
tolerated.  Do not give acetylsalicylic acid (aspirin) to 
children because of  the risks of  Reye’s syndrome.
Antiemetics
Vomiting is common in acute malaria and may be 
severe. It is not known if  antiemetics are effective but 
there is no evidence that they are harmful, though they 
can mask severe malaria. Patients that vomit everything, 
including anti-malarials, should be managed as severe 
malaria.
Health education 
Public education should be given at health facilities 
and schools, and by pharmacists and anyone prescribing 
and dispensing anti-malarials. This can:
• improve the understanding of  malaria
• improved adherence to full treatment
• minimize the use of  inappropriate anti-malarials.
• promote the use of  malaria prevention tools 
especially insecticide-treated bed nets (ITNs). 
HIV infection
 Worsening HIV-related immunosuppression may 
lead to more severe manifestations of  malaria. In stable 
endemic areas, HIV-infected patients with partial immunity 
to malaria may suffer more frequent and higher density 
infections. It is recommended that:
• patients with HIV infection who develop malaria 
should receive prompt, effective anti-malarial treatment 
regimens as recommended in the relevant sections of  the 
WHO guidelines (1).
• intermittent preventive treatment with 
sulfadoxine-pyrimethamine should not be given to HIV-
infected patients receiving cotrimoxazole (trimethoprim 
plus sulfamethoxazole) prophylaxis.
•  treatment in HIV-infected patients on zidovudine 
or efavirenz should, if  possible, avoid amodiaquine-
containing ACT regimens.
• the use of  malaria prevention tools like insecticide-
treated bed nets should also be promoted in HIV-infected 
individuals.
References
Cornelio C.O. & Seriano F. Malaria in South Sudan: 1. 
1. Introduction and pathophysiology SSMJ. 2011. 
1(1):7-9
Attwood D. Malaria in South Sudan: 2. Clinical features 2. 
and diagnosis SSMJ. 2011. 1(1):10-12
Cornelio C.O.Malaria in South Sudan: 3. Laboratory 3. 
diagnosis SSMJ. 2011. 1(1):13-16
WHO Guidelines for the treatment of  malaria. Second 4. 
edition 2010
Ministry of  Health GOSS. Guidelines for management 5. 
of  malaria in Southern Sudan 2008
Ministry of  Health GOSS. Southern Sudan introduces 6. 
Fixed-dose Artesunate Amodiaquine. Malaria Control 
Department.
Note: This article is based on the powerpoint presentation ‘Drug treatment of  
malaria’ by Jane Achan
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PREgnAnT WOMEn AnD yOung InFAnTS
Pregnant women should not take Artesunate/Amodiaquine or Artemether/Lumefantrine in the first trimester. Artemether/
Lumefantrine is contraindicated for children below 5kg body weight. Such patients should be treated with oral Quinine (at a dose 
of  10mg/kg). In very young infants it is important to exclude other causes of  fever.
